Basic Information
| LncRNA/CircRNA Name | circENTPD7 |
| Synonyms | circ_0019421 |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioblastoma |
| ICD-0-3 | NA |
| Methods | Dual luciferase reporter assays, RNA-RNA pulldown assay |
| Sample | glioblastoma tissues |
| Expression Pattern | up-regulated |
| Function Description | circENTPD7 (hsa_circ_0019421) was upregulated in glioblastoma tissues. Kaplan-Meier survival analysis indicated that glioblastoma patients had a poor overall survival when circENTPD7 expression levels were high. Knockdown of circENTPD7 inhibited the motility and proliferation of glioblastoma cells. |
| Pubmed ID | 32308563 |
| Year | 2020 |
| Title | A novel circular RNA circENTPD7 contributes to glioblastoma progression by targeting ROS1 |
External Links
| Links for circENTPD7 | GenBank HGNC NONCODE |
| Links for glioblastoma | OMIM COSMIC |